Posted by Michael Wonder on 09 Apr 2025
Outlook Therapeutics announces acceptance of biologics license application by US FDA for ONS-5010 as a treatment for wet AMD
8 April 2025 - PDUFA goal date of 27 August 2025.
Outlook Therapeutics today announced that the US FDA has acknowledged receipt of the resubmission of the biologics license application for ONS-5010 (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet AMD.
